The downregulation of EMI1 arrests cells in G2 phase of cell cycle, tumor cells that remain in G1- or G2-phase longer are less sensitive to PARP-inhibitor-induced cytotoxicity [29]. This evidence concerns the gene PARP1 and neoplasm.